Last reviewed · How we verify
Ropivacaine injection
Ropivacaine injection, marketed by Zealand University Hospital, is an established anesthetic in the healthcare sector. A key strength is the protection of its core composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the potential increase in competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Ropivacaine injection |
|---|---|
| Also known as | Ropivacaine, Quadratus lumborum block, ropivacaine, ketorolac, epinephrine |
| Sponsor | Zealand University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. (PHASE3)
- Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery (NA)
- CPL-01 in the Management of Postoperative Pain After Bunionectomy (PHASE3)
- Herniorrhaphy for Postoperative Pain (PHASE3)
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Erector Spinae Plane Block for Acute Low Back Pain (NA)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine injection CI brief — competitive landscape report
- Ropivacaine injection updates RSS · CI watch RSS
- Zealand University Hospital portfolio CI